HomeCompareCRHCF vs PFE

CRHCF vs PFE: Dividend Comparison 2026

CRHCF yields 2.39% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRHCF wins by $1.41M in total portfolio value
10 years
CRHCF
CRHCF
● Live price
2.39%
Share price
$53.56
Annual div
$1.28
5Y div CAGR
70.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.46M
Annual income
$1,047,804.46
Full CRHCF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CRHCF vs PFE

📍 CRHCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRHCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRHCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRHCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRHCF
Annual income on $10K today (after 15% tax)
$203.13/yr
After 10yr DRIP, annual income (after tax)
$890,633.79/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CRHCF beats the other by $868,313.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRHCF + PFE for your $10,000?

CRHCF: 50%PFE: 50%
100% PFE50/50100% CRHCF
Portfolio after 10yr
$752.8K
Annual income
$537,031.59/yr
Blended yield
71.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CRHCF
Analyst Ratings
7
Buy
4
Hold
1
Sell
Consensus: Buy
Altman Z
3.0
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRHCF buys
0
PFE buys
0
No recent congressional trades found for CRHCF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRHCFPFE
Forward yield2.39%6.13%
Annual dividend / share$1.28$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR70.8%13.2%
Portfolio after 10y$1.46M$49.6K
Annual income after 10y$1,047,804.46$26,258.71
Total dividends collected$1.40M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: CRHCF vs PFE ($10,000, DRIP)

YearCRHCF PortfolioCRHCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,108$408.17$9,153$693.39+$2.0KCRHCF
2$12,609$723.75$8,593$849.25+$4.0KCRHCF
3$14,804$1,311.43$8,336$1,066.78+$6.5KCRHCF
4$18,297$2,457.65$8,437$1,384.80+$9.9KCRHCF
5$24,427$4,848.96$9,013$1,875.40+$15.4KCRHCF
6$36,470$10,333.24$10,306$2,680.72+$26.2KCRHCF
7$63,650$24,626.72$12,820$4,101.38+$50.8KCRHCF
8$136,713$68,607.03$17,673$6,826.70+$119.0KCRHCF
9$381,507$235,224.40$27,543$12,591.86+$354.0KCRHCF
10$1,456,017$1,047,804.46$49,560$26,258.71+$1.41MCRHCF

CRHCF vs PFE: Complete Analysis 2026

CRHCFStock

CRH plc, through its subsidiaries, manufactures and distributes building materials. It operates in three segments: Americas Materials, Europe Materials, and Building Products. The company manufactures and supplies cement, lime, aggregates, precast, ready mixed concrete, and asphalt products; concrete masonry and hardscape products comprising pavers, blocks and kerbs, retaining walls, and related patio products; and glass and glazing products, including architectural glass, custom-engineered curtain and window walls, architectural windows, storefront systems, doors, skylights, and architectural hardware. It also offers precast concrete and polymer-based products, such as underground vaults, drainage pipes and structures, utility enclosures, and modular precast structures to the water, energy, communication, transportation, and building structures markets; and construction accessories, such as anchoring, fixing, and connection solutions, as well as lifting systems, formwork accessories, and other accessories used in construction applications. In addition, the company offers network access products, which include composite access chambers, covers, passive safety systems, retention sockets, sealants, and meter boxes; and paving and construction services. Further, it provides building and civil engineering contracting, contract surfacing, operates logistics and owned railway infrastructure; sells and distributes cement; and supplies access chambers and ducting products. It serves governments, contractors, homebuilders, homeowners, and sub-contractors. The company operates primarily in the Republic of Ireland, the United Kingdom, the rest of Europe, the United States, and internationally. CRH plc was founded in 1936 and is headquartered in Dublin, Ireland.

Full CRHCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CRHCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRHCF vs SCHDCRHCF vs JEPICRHCF vs OCRHCF vs KOCRHCF vs MAINCRHCF vs JNJCRHCF vs MRKCRHCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.